In the hbopathy session, Fiona Regan is talking on implication of technology on provision of blood in the UK #BSH2019
Current guidance advocates full Rh and kell matching for hbopathy patients, and many would like it for MDS too. But this is not being achieved. Extended matching (MNSs, Fy, Jk) would be even better, but currently not feasible... #BSH2019
Not enough donors are typed, and even if they were, there are not enough donors with the types required. Shorter shelf life for hbopthy (e.g. 7 days for red cell exchange) adds further restraints #BSH2019
Providing matched blood for those without abs risks jeopardising supply to those who already have them #BSH2019
Lots of children are on exchange programmes and the need for red cells for hbopathy patients is only going to increase. Alternative methods are needed to increase the supply of suitable blood #BSH2019
Could genotyping provide the answer? High cost but could be effective in large numbers #BSH2019
20% donors drop off every year due to ineligibility to donate. A lot of work is required just to maintain current levels. Many drives in recent years to encourage BAME donors to donate #BSH2019
Variant alleles (Rh and others) cause further complexities #BSH2019
• • •
Missing some Tweet in this thread? You can try to
force a refresh
